Reizdarmsyndrom – Vom Nihilismus zur pathophysiologisch gesteuerten Therapie
暂无分享,去创建一个
[1] G. Stoddard,et al. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome – a pilot study , 2012, Scandinavian journal of gastroenterology.
[2] C. Lam,et al. An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome , 2012, Journal of neurogastroenterology and motility.
[3] I. Hall,et al. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα , 2012, Gut.
[4] A. Dorofeyev,et al. Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome , 2011, Clinical and experimental gastroenterology.
[5] G. Barlow,et al. Effects of Rifaximin Treatment and Retreatment in Nonconstipated IBS Subjects , 2011, Digestive Diseases and Sciences.
[6] J. Oldenburg,et al. Evidence for Mast Cell Activation in Patients with Therapy-Resistant Irritable Bowel Syndrome , 2011, Zeitschrift fur Gastroenterologie.
[7] P. Enck,et al. [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. , 2011, Zeitschrift fur Gastroenterologie.
[8] W. Chey,et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. , 2011, The New England journal of medicine.
[9] G. Boeckxstaens,et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome , 2010, Gut.
[10] D. Santini,et al. Mucosal Immune Activation in Irritable Bowel Syndrome: Gender-Dependence and Association With Digestive Symptoms , 2009, The American Journal of Gastroenterology.
[11] D. Drossman,et al. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[12] P. Moayyedi,et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review , 2008, Gut.
[13] F. Casellas,et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum , 2006, Gut.
[14] J. Hyams. Functional gastrointestinal disorders. , 1999, Current opinion in pediatrics.
[15] O. Nyrén,et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. , 1995, Gastroenterology.
[16] N. Chaudhary,et al. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. , 1962, The Quarterly journal of medicine.